GENELUX Corp Logo

GENELUX Corp

Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.

GNLX | US

Overview

Corporate Details

ISIN(s):
US36870H1032
LEI:
Country:
United States of America
Address:
2625 TOWNSGATE ROAD, SUITE 230, 91361 WESTLAKE VILLAGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genelux Corporation is a late clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for patients with difficult-to-treat cancers. The company's core technology is a therapeutics and diagnostics platform based on a proprietary, highly customizable vaccinia virus (VACV) backbone. Its lead clinical candidate, Olvi-Vec, is a modified oncolytic vaccinia virus undergoing a registrational Phase 3 trial for platinum-resistant/refractory ovarian cancer. Product development is accelerated by the proprietary CHOICE™ discovery platform, which enables the rapid generation of new viral candidates. Genelux aims to create versatile, "off-the-shelf" immunotherapies with systemic administration potential for a broad range of solid and metastatic tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all GENELUX Corp filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GENELUX Corp

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GENELUX Corp via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.